KR101940939B1 - 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법 - Google Patents

돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법 Download PDF

Info

Publication number
KR101940939B1
KR101940939B1 KR1020177017169A KR20177017169A KR101940939B1 KR 101940939 B1 KR101940939 B1 KR 101940939B1 KR 1020177017169 A KR1020177017169 A KR 1020177017169A KR 20177017169 A KR20177017169 A KR 20177017169A KR 101940939 B1 KR101940939 B1 KR 101940939B1
Authority
KR
South Korea
Prior art keywords
seq
difficile
toxin
amino acid
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177017169A
Other languages
English (en)
Korean (ko)
Other versions
KR20170077263A (ko
Inventor
카트린 우테 얀센
아날리에사 시빌 앤더슨
로버트 지.케이. 도날드
마이클 제임스 핀트
네이렌더 쿠마르 칼리안
제이슨 아놀드 로트빈
만니더 케이 시두
저스틴 케이쓰 모란
마크 에드워드 루펜
웨이퀴앙 선
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20170077263A publication Critical patent/KR20170077263A/ko
Application granted granted Critical
Publication of KR101940939B1 publication Critical patent/KR101940939B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C12R1/145—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020177017169A 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법 Active KR101940939B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261716605P 2012-10-21 2012-10-21
US61/716,605 2012-10-21
PCT/IB2013/059183 WO2014060898A2 (en) 2012-10-21 2013-10-07 Compositions and methods relating to a mutant clostridium difficile toxin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157009888A Division KR101751822B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197001177A Division KR101990272B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20170077263A KR20170077263A (ko) 2017-07-05
KR101940939B1 true KR101940939B1 (ko) 2019-01-21

Family

ID=49546596

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020177017169A Active KR101940939B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020207003847A Active KR102169216B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020157009888A Active KR101751822B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020197016516A Active KR102078517B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020197001177A Active KR101990272B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020207003847A Active KR102169216B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020157009888A Active KR101751822B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020197016516A Active KR102078517B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법
KR1020197001177A Active KR101990272B1 (ko) 2012-10-21 2013-10-07 돌연변이체 클로스트리디움 디피실레 독소에 관한 조성물 및 방법

Country Status (19)

Country Link
US (5) US10787652B2 (enExample)
EP (2) EP2909307B1 (enExample)
JP (4) JP6527661B2 (enExample)
KR (5) KR101940939B1 (enExample)
CN (2) CN108004286B (enExample)
AU (5) AU2013333532C1 (enExample)
BR (2) BR122016023101B1 (enExample)
CA (2) CA2887891C (enExample)
DK (1) DK2909307T3 (enExample)
ES (1) ES2878551T3 (enExample)
HR (1) HRP20211170T1 (enExample)
HU (1) HUE055594T2 (enExample)
IL (3) IL237792B (enExample)
MX (2) MX369289B (enExample)
PL (1) PL2909307T3 (enExample)
PT (1) PT2909307T (enExample)
RU (1) RU2630671C2 (enExample)
SI (1) SI2909307T1 (enExample)
WO (1) WO2014060898A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047085T2 (hu) * 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
CA2976976C (en) * 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
KR101729251B1 (ko) 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101723167B1 (ko) 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
WO2017040885A1 (en) * 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
CN106801077A (zh) * 2017-02-13 2017-06-06 江南大学 一种高效杀灭滴虫等医学原虫的细菌培养上清液的制备方法和及其利用
MX2020003756A (es) * 2017-09-28 2020-07-29 Pfizer Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California VACCINE COMPOSITION FOR CLOSTRIDIUM DIFFICILE
AU2021267172A1 (en) * 2020-05-06 2022-12-08 Albert Einstein College Of Medicine Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins TcdA and TcdB
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
KR20240159001A (ko) 2022-03-14 2024-11-05 화이자 인코포레이티드 보조제의 제조 방법
KR20250120405A (ko) 2022-12-13 2025-08-08 화이자 인코포레이티드 클로스트리디오이데스 (클로스트리디움) 디피실레에 대한 면역 반응을 도출하기 위한 면역원성 조성물 및 방법
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4530833A (en) * 1982-09-13 1985-07-23 Wilkins Tracy D Toxins and antibodies of C. difficile
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
EP0154064A1 (en) * 1984-03-02 1985-09-11 Tracy Dale Wilkins Toxins and antibodies of C. difficile
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
WO1992018652A1 (en) 1991-04-22 1992-10-29 Massachusetts Health Research Institute, Inc. Process of screening plasma samples for effective antibody titers against respiratory viruses
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
CA2158651C (en) 1993-03-29 2009-09-01 David S. Roberts Multicomponent clostridial vaccines using saponin adjuvants
JPH10505358A (ja) 1994-09-06 1998-05-26 ギャラゲン・インコーポレイテッド クロストリジウム・ディフィシル関連疾患の治療処置
CZ296806B6 (cs) 1994-10-24 2006-06-14 Allergan, Inc. Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
CN1195993A (zh) 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
ATE195878T1 (de) 1995-07-07 2000-09-15 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
ES2248822T3 (es) 1995-09-15 2006-03-16 Dale N. Gerding Procedimientos y composiciones para la prevencion y el tratamiento de enfermedades asociadas al clostridium difficile.
AU715555B2 (en) 1996-09-30 2000-02-03 University Of Arkansas, The Method of producing active immunity with vaccine conjugate
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
ATE441432T1 (de) 1997-03-10 2009-09-15 Ottawa Hospital Res Inst Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
JP2002542169A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
PL203951B1 (pl) 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
PL365453A1 (en) 2000-05-04 2005-01-10 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
ES2279869T3 (es) 2001-06-20 2007-09-01 Ramot At Tel Aviv University Ltd. Peptido antigenico comprendido por mulitples copias de un epitope de un polipeptido implicado en enfermedades de formacion de placas y los procedimientos de uso correspondientes.
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
AU2005206951B2 (en) 2004-01-16 2010-08-19 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
NZ530709A (en) * 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
AU2005321974B2 (en) 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
KR20070116710A (ko) * 2005-03-03 2007-12-11 알러간, 인코포레이티드 보툴리눔 독소를 정제하기 위한 동물 산물이 없는 시스템및 프로세스
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
WO2007090126A2 (en) 2006-01-30 2007-08-09 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
WO2008024769A2 (en) 2006-08-21 2008-02-28 Raven Biotechnologies, Inc. Intensified perfusion production method
EP2124556B1 (en) * 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
JP5503543B2 (ja) 2007-09-14 2014-05-28 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物
WO2009132082A2 (en) 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
EP2288719A4 (en) 2008-05-15 2012-01-11 Univ Tufts METHOD FOR DIAGNOSIS OF CLOSTRIDIUM DIFFICILE AND METHOD AND VECTORS FOR RECOMBINANT TOXINEXPRESSION
US9421251B2 (en) 2008-06-25 2016-08-23 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
US20120020996A1 (en) 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
WO2010036826A1 (en) 2008-09-24 2010-04-01 Sanofi Pasteur Biologics Co. Methods and compositions for increasing toxin production
EP2346523A4 (en) * 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
MX2011005758A (es) 2008-12-03 2011-06-28 Boehringer Ingelheim Vetmed Procedimiento para la produccion de vacunas.
CN102333538B (zh) 2008-12-09 2014-01-15 科勒制药集团有限公司 免疫刺激性寡核苷酸
GB0901001D0 (en) 2009-01-22 2009-03-04 Univ Nottingham Methods
WO2010094970A1 (en) 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
KR20120061053A (ko) 2009-08-27 2012-06-12 시냅틱 리서치, 엘엘씨 유도 만능 줄기(ｉＰＳ) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
EP2519257A4 (en) 2009-12-02 2014-10-15 Univ Tufts ATOXIC RECOMBINANT HOLOTOXINS FROM CLOSTRIDIUM DIFFICILE AS IMMUNOGENESIS
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
MX343356B (es) * 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
US8765399B2 (en) * 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
WO2012028418A1 (en) * 2010-09-02 2012-03-08 Novacem Limited Integrated process for producing compositions containing magnesium
HUE033342T2 (en) * 2010-09-03 2017-11-28 Valneva Austria Gmbh Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US9285372B2 (en) 2010-11-12 2016-03-15 Reflexion Pharmaceuticals, Inc. Methods and compositions for identifying D-peptidic compounds that specifically bind target proteins
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
HUE047085T2 (hu) * 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai
DK2714910T3 (en) * 2011-05-27 2018-02-05 Glaxosmithkline Biologicals Sa Immunogenic composition
US9770500B2 (en) 2011-05-31 2017-09-26 The Board Of Regents Of The University Of Texas System S-nitrosylation of glucosylating toxins and uses therefor
US20150071958A1 (en) * 2011-11-30 2015-03-12 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
CA2858519A1 (en) 2011-12-08 2013-06-13 Novartis Ag Clostridium difficile toxin-based vaccine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CA2882620A1 (en) * 2012-09-19 2014-03-27 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
DK2928489T3 (en) * 2012-12-05 2019-04-23 Glaxosmithkline Biologicals Sa IMMUNOGENE COMPOSITION
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CN105338997A (zh) * 2013-03-15 2016-02-17 圣诺菲·帕斯图尔公司 类毒素、组合物和相关的方法
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
EP2981611A4 (en) 2013-04-02 2016-11-16 Stc Unm ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
EP3060246A4 (en) * 2013-10-23 2017-08-16 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3005308C (en) 2015-11-17 2022-01-04 Pfizer Inc. Media and fermentation methods for producing polysaccharides in bacterial cell culture
US10813988B2 (en) * 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
CA3016351A1 (en) 2017-09-05 2019-03-05 Mcmaster University Aptamers for clostridium difficile detection
MX2020003756A (es) 2017-09-28 2020-07-29 Pfizer Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
EP4168032A2 (en) 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, Vol.106, pp.13225-13229(2009.08.11.)

Also Published As

Publication number Publication date
RU2015112079A (ru) 2016-12-10
CN108004286A (zh) 2018-05-08
EP3912990A1 (en) 2021-11-24
EP2909307A2 (en) 2015-08-26
HK1254448A1 (zh) 2019-07-19
KR20200017552A (ko) 2020-02-18
JP7208293B2 (ja) 2023-01-18
US10982198B2 (en) 2021-04-20
JP6871969B2 (ja) 2021-05-19
MX369289B (es) 2019-11-04
US20200165582A1 (en) 2020-05-28
KR102078517B1 (ko) 2020-02-18
CN104797706B (zh) 2020-05-26
CA3063892A1 (en) 2014-04-24
CA3063892C (en) 2023-05-09
BR112015008844A8 (pt) 2018-04-03
IL284582B2 (en) 2023-04-01
KR101990272B1 (ko) 2019-06-17
PT2909307T (pt) 2021-07-14
KR20190069604A (ko) 2019-06-19
KR20170077263A (ko) 2017-07-05
WO2014060898A3 (en) 2014-06-12
US20190112584A1 (en) 2019-04-18
JP6527661B2 (ja) 2019-06-05
BR112015008844A2 (pt) 2017-11-21
HUE055594T2 (hu) 2021-12-28
AU2017201193C1 (en) 2019-10-24
MX2019013075A (es) 2019-12-16
CA2887891A1 (en) 2014-04-24
KR102169216B1 (ko) 2020-10-22
AU2013333532B2 (en) 2016-11-24
IL284582A (en) 2021-08-31
BR122016023101B1 (pt) 2022-03-22
US20250002875A1 (en) 2025-01-02
AU2013333532A1 (en) 2015-04-02
US11208633B2 (en) 2021-12-28
MX379863B (es) 2025-03-11
US20210024903A1 (en) 2021-01-28
CN108004286B (zh) 2022-03-08
AU2021277590A1 (en) 2021-12-23
PL2909307T3 (pl) 2022-11-07
HRP20211170T1 (hr) 2021-11-12
AU2020203423A1 (en) 2020-06-11
HK1212385A1 (en) 2016-06-10
AU2013333532C1 (en) 2019-10-24
BR122016023101A2 (pt) 2019-08-27
BR112015008844B1 (pt) 2022-03-22
MX2015004986A (es) 2015-07-17
IL237792A0 (en) 2015-05-31
AU2017201193B2 (en) 2019-02-07
IL284582B (en) 2022-12-01
ES2878551T3 (es) 2021-11-19
CA2887891C (en) 2023-03-07
SI2909307T1 (sl) 2021-08-31
AU2019203159B2 (en) 2020-05-07
US10787652B2 (en) 2020-09-29
AU2019203159A1 (en) 2019-05-30
IL271064A (en) 2020-01-30
KR20190008988A (ko) 2019-01-25
JP2014083054A (ja) 2014-05-12
KR20150056843A (ko) 2015-05-27
JP7556987B2 (ja) 2024-09-26
CN104797706A (zh) 2015-07-22
RU2630671C2 (ru) 2017-09-11
AU2017201193A1 (en) 2017-03-16
JP2019150045A (ja) 2019-09-12
KR101751822B1 (ko) 2017-06-28
DK2909307T3 (da) 2021-07-05
IL271064B (en) 2021-07-29
US11952597B2 (en) 2024-04-09
EP2909307B1 (en) 2021-05-26
JP2021119775A (ja) 2021-08-19
WO2014060898A2 (en) 2014-04-24
JP2023036952A (ja) 2023-03-14
IL237792B (en) 2021-03-25
US20150291940A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
AU2020230248B2 (en) Compositions relating to a mutant Clostridium difficile toxin and methods thereof
AU2019203159B2 (en) Compositions and methods relating to a mutant clostridium difficile toxin
KR102625114B1 (ko) 클로스트리디움 디피실레에 대항한 면역 반응을 도출하기 위한 조성물 및 방법
RU2773880C1 (ru) Композиции, относящиеся к мутантному токсину CLOSTRIDIUM DIFFICILE, и способы их применения
HK1254448B (en) Compositions and methods relating to a mutant clostridium difficile toxin

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170622

Application number text: 1020157009888

Filing date: 20150416

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181005

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20181017

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190114

Application number text: 1020157009888

Filing date: 20150416

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20241223

Start annual number: 7

End annual number: 7